FindTrial
Sign In

Lomvastomig

DRUG2 trials

Sponsors

Hoffmann-La Roche

Conditions

Advanced or Metastatic Esophageal Squamous Cell CarcinomaEsophageal Squamous Cell Carcinoma (ESCC)Metastatic MelanomaNon-small Cell Lung Cancer (NSCLC)Small Cell Lung Cancer (SCLC)Solid Tumors

Phase 1

A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors
CompletedNCT03708328
Hoffmann-La RocheEsophageal Squamous Cell Carcinoma (ESCC), Metastatic Melanoma, Non-small Cell Lung Cancer (NSCLC) +2
Start: 2018-10-15End: 2024-07-09Updated: 2025-08-20

Phase 2

A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
CompletedNCT04785820
Hoffmann-La RocheAdvanced or Metastatic Esophageal Squamous Cell Carcinoma
Start: 2021-06-25End: 2025-01-30Updated: 2026-03-27

Related Papers

First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors.
2026-06-19
Abstract 2270: RG7769 (PD1-TIM3), a novel heterodimeric avidity-driven T cell specific PD-1/TIM-3 bispecific antibody lacking Fc-mediated effector functions for dual checkpoint inhibition to reactivate dysfunctional T cells
Cancer Research2020-08-1514 citations